<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Ophthalmic surgery products - Moria - Alchimia</title>
	<atom:link href="https://alchimiasrl.com/information/ophthalmic-surgery-fr/feed/" rel="self" type="application/rss+xml" />
	<link>https://alchimiasrl.com/information/ophthalmic-surgery-fr/</link>
	<description>Your ideas, our solutions</description>
	<lastBuildDate>Fri, 06 Mar 2020 09:17:51 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://alchimiasrl.com/wp-content/uploads/2020/03/cropped-Icon-per-sito-32x32.jpg</url>
	<title>Ophthalmic surgery products - Moria - Alchimia</title>
	<link>https://alchimiasrl.com/information/ophthalmic-surgery-fr/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Release of silicone oil and the off-label use of syringes in ophthalmology</title>
		<link>https://alchimiasrl.com/release-of-silicone-oil-and-the-off-label-use-of-syringes-in-ophthalmology/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Wed, 27 Mar 2019 15:45:52 +0000</pubDate>
				<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Publications]]></category>
		<category><![CDATA[RS-OIL]]></category>
		<category><![CDATA[Silicone oils]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/non-classifiee/release-of-silicone-oil-and-the-off-label-use-of-syringes-in-ophthalmology/</guid>

					<description><![CDATA[<p>Year: 2019 Authors: Gustavo Barreto Melo G. B.; Emerson G. G.; Dias Jr C. S.; Barreto Morais F.; de Souza Lima Filho A.; Ota S.; Eid Farah M.; Büchele Rodrigues E.; Maia M.; Belfort Jr R. Category: Laboratory science     BMJ Open Opthalmology doi: 10.1136/bjophthalmol-2019-313823 Online version This is a: Publication   [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/release-of-silicone-oil-and-the-off-label-use-of-syringes-in-ophthalmology/">Release of silicone oil and the off-label use of syringes in ophthalmology</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-1 hover-type-none"><img decoding="async" width="200" height="200" title="BMJ Open Ophthalmology 200" src="https://alchimiasrl.com/wp-content/uploads/2018/11/BMJ-Open-Ophthalmology-200.png" alt class="img-responsive wp-image-13121" srcset="https://alchimiasrl.com/wp-content/uploads/2018/11/BMJ-Open-Ophthalmology-200-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/11/BMJ-Open-Ophthalmology-200-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/11/BMJ-Open-Ophthalmology-200-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/11/BMJ-Open-Ophthalmology-200.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-1"><p><strong>Year: </strong>2019</p>
<p><strong>Authors</strong>: Gustavo Barreto Melo G. B.; Emerson G. G.; Dias Jr C. S.; Barreto Morais F.; de Souza Lima Filho A.; Ota S.; Eid Farah M.; Büchele Rodrigues E.; Maia M.; Belfort Jr R.</p>
<p><strong>Category:</strong> Laboratory science</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:0px;margin-bottom:0px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-2"><p>BMJ Open Opthalmology<br />
doi: 10.1136/bjophthalmol-2019-313823<br />
<a href="https://bjo.bmj.com/content/early/2019/03/24/bjophthalmol-2019-313823">Online version</a></p>
</div><div class="fusion-text fusion-text-3"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-4"><p><strong>Background/aims:</strong> To assess silicone oil (SO) release by different brands of syringes used for intravitreal injection under different handling conditions.</p>
<p><strong>Methods:</strong> Eight syringes were analysed: from the USA, Terumo 0.5 mL, Becton-Dickinson (BD) Tuberculin 1 mL, BD Luer-lok 1 mL, BD Ultra-Fine 0.3 mL and Exel Insulin 0.3 mL; from Germany, Braun Omnifx-F 1 mL and Braun Injekt-F 1 mL and from Spain, BD Plastipak 1 mL.<br />
Theimpact of air, priming the plunger, agitation by ﬂicking and ﬂuid temperature on SO release were assessed by light microscopy. Fourier transform infrared spectroscopy (FTIR) was performed to identify the molecular compound in each syringe.</p>
<p><strong>Results:</strong> Five hundred and sixty syringes were analysed.<br />
Terumo 0.5 mL and BD Ultra-Fine 0.3 mL released more SO than all others. BD Luer-lok 1 mL, BD Plastipak and Braun Omnifx-F 1 mL released little SO; BD Tuberculin 1 mL, Exel 0.3 mL and Braun Injekt-F 1 mL released the least SO. Priming the syringe and different temperatures did not signifcantly affect SO release. Agitation by ﬂicking caused a signifcantly higher proportion of samples to have SO droplets and an increased number of oil droplets. Air had an additive effect on the release of oil in the agitation groups. FTIR identifed polysiloxane in all syringes but Injekt-F.</p>
<p><strong>Conclusion:</strong> Syringes commonly used for intravitreal injections frequently release SO droplets, especially when agitated by ﬂicking. To avoid unnecessary ocular risks, syringes should not be agitated before intravitreal injection. It is desirable that syringes be manufactured specifcally for ophthalmic use.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/release-of-silicone-oil-and-the-off-label-use-of-syringes-in-ophthalmology/">Release of silicone oil and the off-label use of syringes in ophthalmology</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Effect of intraoperative use of a polymeric blend on postoperative corneal epithelial cell changes and ocular comfort in cataract surgery</title>
		<link>https://alchimiasrl.com/effect-of-intraoperative-use-of-a-polymeric-blend-on-postoperative-corneal-epithelial-cell-changes-and-ocular-comfort-in-cataract-surgery/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Sun, 04 Nov 2018 16:26:36 +0000</pubDate>
				<category><![CDATA[AAO]]></category>
		<category><![CDATA[EuCornea]]></category>
		<category><![CDATA[eyeDRO]]></category>
		<category><![CDATA[Meeting presentations]]></category>
		<category><![CDATA[Ophthalmic gels]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/non-classifiee/effect-of-intraoperative-use-of-a-polymeric-blend-on-postoperative-corneal-epithelial-cell-changes-and-ocular-comfort-in-cataract-surgery/</guid>

					<description><![CDATA[<p>Year: 2018, Eucornea and AAO Authors: Mencucci R.; Favuzza E.; Cennamo M.   Background: The corneal coating gel reduces corneal injury and improve patient comfort. In the present study we monitored inflammation and epithelial remodelling parameters in coating gel- and BSS-treated eyes up to 30 days postop. Purpose: To study the effects on corneal surface and  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/effect-of-intraoperative-use-of-a-polymeric-blend-on-postoperative-corneal-epithelial-cell-changes-and-ocular-comfort-in-cataract-surgery/">Effect of intraoperative use of a polymeric blend on postoperative corneal epithelial cell changes and ocular comfort in cataract surgery</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-2 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-2 hover-type-none"><img decoding="async" width="200" height="200" title="L_EUCORNEA 200" src="https://alchimiasrl.com/wp-content/uploads/2018/11/L_EUCORNEA-200.png" alt class="img-responsive wp-image-13463" srcset="https://alchimiasrl.com/wp-content/uploads/2018/11/L_EUCORNEA-200-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/11/L_EUCORNEA-200-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/11/L_EUCORNEA-200-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/11/L_EUCORNEA-200.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-3 hover-type-none"><img decoding="async" width="200" height="200" title="AAO 200 SITE" src="https://alchimiasrl.com/wp-content/uploads/2018/11/AAO-200-SITE.png" alt class="img-responsive wp-image-12371" srcset="https://alchimiasrl.com/wp-content/uploads/2018/11/AAO-200-SITE-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/11/AAO-200-SITE-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/11/AAO-200-SITE-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/11/AAO-200-SITE.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-5"><p><strong>Year:</strong> 2018, Eucornea and AAO</p>
<p><strong>Authors</strong>: <span class="fontstyle0">Mencucci R.; Favuzza E.; Cennamo M.</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-6"><p><strong><span class="fontstyle0">Background: </span></strong><span class="fontstyle0">The corneal coating gel reduces </span><span class="fontstyle0">corneal injury and improve patient comfort. In the present study we monitored inflammation and epithelial remodelling parameters in coating gel- and BSS-treated eyes up to 30 days postop.</span><strong><span class="fontstyle0"><br />
</span></strong></p>
<p><strong><span class="fontstyle0">Purpose: </span></strong><span class="fontstyle2">To study the effects on corneal surface and discomfort syndrome after cataract surgery using intraoperative tripolymeric coating gel.<br />
</span></p>
<p><span class="fontstyle0"><strong>Methods:</strong> </span><span class="fontstyle2">25 eyes received the corneal coating gel during surgery; 25 eyes were irrigated with BSS (control). Anterior segment optical coherence tomography (central corneal thickness (CCT), epithelial thickness (ET), confocal microscopy, and ocular surface disease index (OSDI) were administered preoperatively (baseline), 1, 5, and 14 days postoperatively.<br />
</span></p>
<p><strong><span class="fontstyle0">Results: </span></strong><span class="fontstyle2">In the BSS-irrigated eyes, all the parameters changed in postop period and came back to the baseline values after 30 days. In the gel-coated eyes, only CCT and ET increased significantly 1 day postop, whereas all the parameters remained similar to the baseline at all follow-up intervals. OSDI was better in the coating gel group.<br />
</span></p>
<p><strong><span class="fontstyle0">Conclusion: </span></strong><span class="fontstyle2">The use of intraoperative coating gel reduced the effects of surgically induced trauma and improved ocular comfort.</span></p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/effect-of-intraoperative-use-of-a-polymeric-blend-on-postoperative-corneal-epithelial-cell-changes-and-ocular-comfort-in-cataract-surgery/">Effect of intraoperative use of a polymeric blend on postoperative corneal epithelial cell changes and ocular comfort in cataract surgery</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cytotoxicity testing according to ISO 10993-5 of perfluorocarbon manufacturing process residuals</title>
		<link>https://alchimiasrl.com/cytotoxicity-testing-according-to-iso-10993-5-of-perfluorocarbon-manufacturing-process-residuals/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Mon, 24 Sep 2018 16:46:29 +0000</pubDate>
				<category><![CDATA[EURETINA]]></category>
		<category><![CDATA[HPF]]></category>
		<category><![CDATA[Meeting presentations]]></category>
		<category><![CDATA[Ophthalmic gases]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Présentations de R&D]]></category>
		<category><![CDATA[R&D]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/non-classifiee/cytotoxicity-testing-according-to-iso-10993-5-of-perfluorocarbon-manufacturing-process-residuals/</guid>

					<description><![CDATA[<p>Year: 2018, Euretina Authors: Romano M. Co-Authors: Gatto C.; Giurgola L.; Ferrara M.; D'Amato Tóthová J.   Methods: Serial dilutions of perfluorooctanoid acid, 1H,1H,7H-dodecafluoro-1- heptanol, 1H,1H,1H,2H,2H-Perfluorooctane, 1H perfluorooctan; ethylbenzene, paraxylene, perfluotobutyfurane, and hexafluoro-1,2,3,4-tetrachlorobutane were tested by direct contact cytotoxicity test using BALB3T3 and ARPE19 cell lines, after application on 59% of the area for 24 h.  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/cytotoxicity-testing-according-to-iso-10993-5-of-perfluorocarbon-manufacturing-process-residuals/">Cytotoxicity testing according to ISO 10993-5 of perfluorocarbon manufacturing process residuals</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-3 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-4 hover-type-none"><img decoding="async" width="200" height="200" title="Euretina 200" src="https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3.png" alt class="img-responsive wp-image-12355" srcset="https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-7"><p><strong>Year:</strong> 2018, Euretina</p>
<p><strong>Authors</strong>: Romano M.</p>
<p><strong>Co-Authors</strong>: Gatto C.; Giurgola L.; Ferrara M.; D&#8217;Amato Tóthová J.</p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-8"><p><strong> <span class="fontstyle0">Methods</span><span class="fontstyle0">: </span></strong><span class="fontstyle0">Serial dilutions of perfluorooctanoid acid, 1H,1H,7H-dodecafluoro-1- heptanol, 1H,1H,1H,2H,2H-Perfluorooctane, 1H perfluorooctan; ethylbenzene, paraxylene, perfluotobutyfurane, and hexafluoro-1,2,3,4-tetrachlorobutane were tested by direct contact cytotoxicity test using BALB3T3 and ARPE19 cell lines, after application on 59% of the area for 24 h.<br />
</span></p>
<p><strong><span class="fontstyle0">Results</span></strong><span class="fontstyle0"><strong>:</strong> </span><span class="fontstyle0">Traces of paraxylene, ethylbenzene, and PFOA (≤30ppm) induced severe toxicity in both cell lines. Hexafluoro-1,2,3,4-tetrachlorobutane and H,1H,7H-Dodecafluoro-1-heptanol were cytotoxic at approximately 10000 ppm. 1H perfluorooctan was cytotoxic at approximately 60000 ppm. High concentrations of 1H,1H,1H,2H,2H-Perfluorooctane and perfluotobutyfurane were not cytotoxic.<br />
</span></p>
<p><strong><span class="fontstyle0">Conclusions</span></strong><span class="fontstyle0"><strong>:</strong> S</span><span class="fontstyle0">ix out of eight perfluorocarbon manufacturing process residuals showed cytotoxicity in the direct contact test according to ISO 10993-5. Paraxylene, ethylbenzene, and PFOA were the most cytotoxic compounds. 1H,1H,1H,2H,2H-Perfluorooctane and perfluotobutyfurane were not cytotoxic.</span></p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/cytotoxicity-testing-according-to-iso-10993-5-of-perfluorocarbon-manufacturing-process-residuals/">Cytotoxicity testing according to ISO 10993-5 of perfluorocarbon manufacturing process residuals</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Perfluorocarbons for intraocular use: cytotoxicity test validation study according to ISO 10993-5</title>
		<link>https://alchimiasrl.com/perfluorocarbons-for-intraocular-use-cytotoxicity-test-validation-study-according-to-iso-10993-5/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Mon, 24 Sep 2018 16:40:13 +0000</pubDate>
				<category><![CDATA[EURETINA]]></category>
		<category><![CDATA[HPF]]></category>
		<category><![CDATA[Meeting presentations]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Perfluorocarbons]]></category>
		<category><![CDATA[Publications de R&D]]></category>
		<category><![CDATA[R&D]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/non-classifiee/perfluorocarbons-for-intraocular-use-cytotoxicity-test-validation-study-according-to-iso-10993-5/</guid>

					<description><![CDATA[<p>Year: 2018, Euretina Authors: Romano M. Co-Authors: Gatto C.; Giurgola L.; Ferrara M.; D'Amato Tóthová J.   Methods: BALB3T3 and ARPE19 cell lines were cultured in 96-well plates for direct contact cytotoxicity test of 22%, 59%, and 83% contact areas and 2.5, 12, and 24 h contact times. Cell morphology was graded by light microscopy. Cell  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/perfluorocarbons-for-intraocular-use-cytotoxicity-test-validation-study-according-to-iso-10993-5/">Perfluorocarbons for intraocular use: cytotoxicity test validation study according to ISO 10993-5</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-4 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-5 hover-type-none"><img decoding="async" width="200" height="200" title="Euretina 200" src="https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3.png" alt class="img-responsive wp-image-12355" srcset="https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-9"><p><strong>Year:</strong> 2018, Euretina</p>
<p><strong>Authors</strong>: Romano M.</p>
<p><strong>Co-Authors</strong>: Gatto C.; Giurgola L.; Ferrara M.; D&#8217;Amato Tóthová J.</p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-10"><p><strong> <span class="fontstyle0">Methods</span><span class="fontstyle0">: </span></strong><span class="fontstyle0">BALB3T3 and ARPE19 cell lines were cultured in 96-well plates for direct contact cytotoxicity test of 22%, 59%, and 83% contact areas and 2.5, 12, and 24 h contact times. Cell morphology was graded by light microscopy. Cell viability was quantified by MTT assay in ARPE19 cells and neutral red uptake viability assay for BALB3T3. 1-H perfluorooctane (1H PFO) and purified perfluoro-n-octane (PFO) were used as positive and negative controls, respectively.</span></p>
<p><strong><span class="fontstyle0">Results</span><span class="fontstyle0">: </span></strong><span class="fontstyle0">Qualitative evaluation showed that positive control induced the presence of severe reactivity zones, resulting in 2.2 to 3.0 grading score, and cytotoxicity according to ISO 10993-5 in all tested conditions. Quantitative evaluation of 1H PFO applied on 22%, 59%, and 83% contact areas corresponded to 14–26%, 84–96%, and 86–99% cell mortality ranges, respectively. No cytotoxicity according to ISO 10993-5 was detected in tested cell lines, when 1H PFO was applied on a 22% area at the tested time intervals. The negative control was not cytotoxic with both approaches in all tested conditions.<br />
</span></p>
<p><strong><span class="fontstyle0">Conclusions</span><span class="fontstyle0">: </span></strong><span class="fontstyle0">Direct contact cytotoxicity test according to ISO 10993-5 of PFCLs was validated quantitatively and qualitatively, using ARPE19 and BALB 3T3 cell lines and covering 59% of the cell surface areas for 24 h of contact time. Test conditions using a smaller contact area could not be validated.</span></p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/perfluorocarbons-for-intraocular-use-cytotoxicity-test-validation-study-according-to-iso-10993-5/">Perfluorocarbons for intraocular use: cytotoxicity test validation study according to ISO 10993-5</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>25-gauge vitrectomy and gas for the management of rhegmatogenous retinal detachment</title>
		<link>https://alchimiasrl.com/25-gauge-vitrectomy-and-gas-for-the-management-of-rhegmatogenous-retinal-detachment/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Thu, 21 Jun 2018 09:45:46 +0000</pubDate>
				<category><![CDATA[GOT]]></category>
		<category><![CDATA[Ophthalmic gases]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Publications]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/non-classifiee/25-gauge-vitrectomy-and-gas-for-the-management-of-rhegmatogenous-retinal-detachment/</guid>

					<description><![CDATA[<p>Year: 2018 Authors: Veitha M.; Stranaka Z.; Pencaka M.; Vranovab J.; Studenya P.     Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia (Biomed Paper) doi: 10.5507/bp.2018.034 Online version This is a: Publication   Aims: To evaluate the anatomical and functional results in patients with rhegmatogenous retinal detachment  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/25-gauge-vitrectomy-and-gas-for-the-management-of-rhegmatogenous-retinal-detachment/">25-gauge vitrectomy and gas for the management of rhegmatogenous retinal detachment</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-5 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-6 hover-type-none"><img decoding="async" width="200" height="200" title="Biomedical papers" src="https://alchimiasrl.com/wp-content/uploads/2019/04/Biomedical-papers.jpg" alt class="img-responsive wp-image-15493" srcset="https://alchimiasrl.com/wp-content/uploads/2019/04/Biomedical-papers-66x66.jpg 66w, https://alchimiasrl.com/wp-content/uploads/2019/04/Biomedical-papers-100x100.jpg 100w, https://alchimiasrl.com/wp-content/uploads/2019/04/Biomedical-papers-150x150.jpg 150w, https://alchimiasrl.com/wp-content/uploads/2019/04/Biomedical-papers.jpg 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-11"><p><strong>Year: </strong>2018</p>
<p><strong>Authors</strong>: Veitha M.; Stranaka Z.; Pencaka M.; Vranovab J.; Studenya P.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:0px;margin-bottom:0px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-12"><p>Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia (Biomed Paper)<br />
doi: 10.5507/bp.2018.034<br />
<a href="https://www.researchgate.net/publication/326151044_25-gauge_vitrectomy_and_gas_for_the_management_of_rhegmatogenous_retinal_detachment">Online version</a></p>
</div><div class="fusion-text fusion-text-13"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-9 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-14"><p><strong>Aims:</strong> To evaluate the anatomical and functional results in patients with rhegmatogenous retinal detachment (RRD) who underwent 25-gauge pars plana vitrectomy (PPV) with gas tamponade.</p>
<p><strong>Materials and Methods:</strong> A retrospective evaluation of 126 eyes of 126 patients (79 men, 47 women) with RRD who underwent 25-gauge PPV with gas tamponade (13% C3F8 in 87 eyes, 20% SF6 in 39 eyes). 113 patients (89.7%), were operated on under local anaesthesia, 13 patients (10.3%) under general anaesthesia. Macula was detached in 85 eyes (67.5%). 53 eyes had pseudophakic RRD, 73 eyes were phakic. Anatomical success of the primary intervention, change in best corrected visual acuity (BCVA) and incidence of complications were assessed. An average follow-up period is 7.2 months (6-15).</p>
<p><strong>Results:</strong> With single operation, retinal attachment was achieved in 125 eyes (99.2%); the final anatomical success was 100%. The initial mean BCVA was 0.89 logMar (2.00 to 0.00); at the end of the follow-up period, it improved to 0.23logMAR (1.00 to -0.10), P &lt; 0,0001. During the first post-intervention day, hypotony of the eye below 10 mmHg was observed in 1 patient (0.8%); on the contrary, intraocular pressure was temporarily increased to 25 mmHg and more in 36 patients (28.6%).</p>
<p><strong>Conclusion:</strong> The surgical treatment of RRD using 25-gauge PPV with expansive gas tamponade renders excellent anatomical results and improvement in BCVA. The incidence of complications and necessity of sclerotomy suturing are low.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/25-gauge-vitrectomy-and-gas-for-the-management-of-rhegmatogenous-retinal-detachment/">25-gauge vitrectomy and gas for the management of rhegmatogenous retinal detachment</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Tripolymeric Corneal Coating Gel Versus Balanced Salt Solution Irrigation During Cataract Surgery: A Retrospective Analysis</title>
		<link>https://alchimiasrl.com/tripolymeric-corneal-coating-gel-versus-balanced-salt-solution-irrigation-during-cataract-surgery-a-retrospective-analysis/</link>
		
		<dc:creator><![CDATA[fabrizio.penso]]></dc:creator>
		<pubDate>Sat, 03 Feb 2018 12:00:09 +0000</pubDate>
				<category><![CDATA[eyeDRO]]></category>
		<category><![CDATA[Ophthalmic gels]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Publications]]></category>
		<category><![CDATA[Publications de R&D]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[home]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/non-classifiee/tripolymeric-corneal-coating-gel-versus-balanced-salt-solution-irrigation-during-cataract-surgery-a-retrospective-analysis/</guid>

					<description><![CDATA[<p>Year: 2018 Authors: Giardini P.; Hauranieh N.; Gatto C.; D’Amato Tóthová J.     Cornea, doi: 10.1097/ICO.0000000000001480 Online version  This is a: Publication   Purpose: To compare the protective properties and ease of manipulation during cataract surgery of corneal coating with a gel (eyeDRO; AL.CHI.MI.A. S.R.L, Italy) and corneal irrigation with  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/tripolymeric-corneal-coating-gel-versus-balanced-salt-solution-irrigation-during-cataract-surgery-a-retrospective-analysis/">Tripolymeric Corneal Coating Gel Versus Balanced Salt Solution Irrigation During Cataract Surgery: A Retrospective Analysis</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-6 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-10 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-7 hover-type-none"><img decoding="async" width="200" height="200" title="Cornea Journal 200" src="https://alchimiasrl.com/wp-content/uploads/2018/06/Cornea-Journal-200.png" alt class="img-responsive wp-image-13137" srcset="https://alchimiasrl.com/wp-content/uploads/2018/06/Cornea-Journal-200-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/06/Cornea-Journal-200-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/06/Cornea-Journal-200-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/06/Cornea-Journal-200.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-15"><p><strong>Year:</strong> 2018</p>
<p><strong>Authors:</strong> Giardini P.; Hauranieh N.; Gatto C.; D’Amato Tóthová J.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:0px;margin-bottom:0px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-16"><p>Cornea, doi: 10.1097/ICO.0000000000001480<br />
<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844581/">Online version</a></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-17"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-11 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-18"><p><strong>Purpose</strong>: To compare the protective properties and ease of manipulation during cataract surgery of corneal coating with a gel (eyeDRO; AL.CHI.MI.A. S.R.L, Italy) and corneal irrigation with balanced salt solution (BSS).</p>
<p><strong>Methods</strong>: We analyzed the data of 51 patients receiving either eyeDRO or BSS during routine cataract surgery performed within a 20-day period in 2016. The selected parameters were intraoperative clarity and ease of manipulation; postoperative epithelial integrity; and patient discomfort.</p>
<p><strong>Results</strong>: Compared with BSS irrigation, eyeDRO coating significantly increased intraoperative clarity and ease of manipulation (P &lt; 0.01). Single application was required in eyeDRO-treated eyes, whereas BSS was applied 5.3 ± 0.4 times on average (P &lt; 0.01). Two hours postoperatively, a normal epithelium was observed in 90.0% and 60.0% of eyeDRO-coated and BSS-irrigated eyes, respectively; punctate epithelial damage was observed in 9.7% and 40.0% (P &lt; 0.05) of eyeDRO-coated and BSS-irrigated eyes, respectively; eye irritation and foreign body sensation were experienced by 13.0% and 37.0% of eyeDRO-treated patients and by 65.0% and 100% of BSS-treated patients, respectively (P &lt; 0.01). Twenty-four hours postoperatively, 80.0% of BSS-treated patients versus 19.0% of eyeDRO-treated patients still experienced foreign body sensation (P &lt; 0.01).</p>
<p><strong>Conclusions</strong>: eyeDRO coating was shown to be a safer and more effective option than BSS irrigation in cataract surgery because single application provided optimal hydration and intraoperative clarity during the entire surgery, better preserved the corneal epithelium, and offered postoperative comfort to the patient.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/tripolymeric-corneal-coating-gel-versus-balanced-salt-solution-irrigation-during-cataract-surgery-a-retrospective-analysis/">Tripolymeric Corneal Coating Gel Versus Balanced Salt Solution Irrigation During Cataract Surgery: A Retrospective Analysis</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Negative staining of the vitreous with the use of vital dyes</title>
		<link>https://alchimiasrl.com/negative-staining-of-the-vitreous-with-the-use-of-vital-dyes/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Mon, 20 Nov 2017 15:45:09 +0000</pubDate>
				<category><![CDATA[Dyes]]></category>
		<category><![CDATA[EURETINA]]></category>
		<category><![CDATA[Meeting presentations]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Publications]]></category>
		<category><![CDATA[Twin]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/non-classifiee/negative-staining-of-the-vitreous-with-the-use-of-vital-dyes/</guid>

					<description><![CDATA[<p>Year: 2017 Authors: Mariotti C.; Nicolai M.; Donati S.; Reibaldi M.     Eur J Ophthalmol. 2017 Apr 13:0. doi: 10.5301/ejo.5000968 Online version  This is a: Publication   Purpose: The vitreous cortex, epiretinal membrane (ERM), and inner limiting membrane (ILM) are transparent tissues and are then difficult to visualize. Staining these structures can  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/negative-staining-of-the-vitreous-with-the-use-of-vital-dyes/">Negative staining of the vitreous with the use of vital dyes</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-7 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-12 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-8 hover-type-none"><img decoding="async" width="200" height="200" title="EJO 200" src="https://alchimiasrl.com/wp-content/uploads/2017/11/EJO-200.png" alt class="img-responsive wp-image-13156" srcset="https://alchimiasrl.com/wp-content/uploads/2017/11/EJO-200-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2017/11/EJO-200-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2017/11/EJO-200-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2017/11/EJO-200.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-19"><p><strong>Year: </strong>2017</p>
<p><strong>Authors: </strong>Mariotti C.; Nicolai M.; Donati S.; Reibaldi M.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:0px;margin-bottom:0px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-20"><p>Eur J Ophthalmol. 2017 Apr 13:0. doi: 10.5301/ejo.5000968<br />
<a href="https://www.ncbi.nlm.nih.gov/pubmed/28430324">Online version</a></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-21"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-13 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-22"><p><strong>Purpose: </strong>The vitreous cortex, epiretinal membrane (ERM), and inner limiting membrane (ILM) are transparent tissues and are then difficult to visualize. Staining these structures can increase the efficiency of a nontraumatic removal.</p>
<p><strong>Methods:</strong> The surgeon performs a partial core vitrectomy and induces a posterior vitreous detachment. The vital dye is then injected into the retrohyaloid space in balanced salt solution (BSS). The dyes used are TWIN (AL.CHI.MI.A. Srl, Padova, Italy), MembraneBlue-Dual (DORC International, Zuidland, The Netherlands), and Doubledyne (Alfa Intes, Casoria, Italy). The surgeon can complete the vitrectomy and gradually aspirate the dye with a probe. Once the vitrectomy is complete, the surgeon can perform the peeling of the ERM without the need to reinject the vital dye over the macula.</p>
<p><strong>Results:</strong> The presence of the dye over the macula facilitates the visualization of the vitreous cortex by blocking the red reflex and increasing the contrast power of the coaxial light probe during the vitrectomy. This allows a negative staining of the vitreous because the dye acts by increasing the visibility of the surrounding BSS and not the vitreous itself.</p>
<p><strong>Conclusions:</strong> We describe a new chromovitrectomy technique using the same dye to increase the visualization of the vitreous, posterior hyaloid, ERM, and ILM.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/negative-staining-of-the-vitreous-with-the-use-of-vital-dyes/">Negative staining of the vitreous with the use of vital dyes</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dropless cataract surgery</title>
		<link>https://alchimiasrl.com/dropless-cataract-surgery/</link>
		
		<dc:creator><![CDATA[fabrizio.penso]]></dc:creator>
		<pubDate>Thu, 22 Sep 2016 15:25:00 +0000</pubDate>
				<category><![CDATA[ESCRS]]></category>
		<category><![CDATA[eyeDRO]]></category>
		<category><![CDATA[Meeting presentations]]></category>
		<category><![CDATA[Ophthalmic gels]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Présentations de R&D]]></category>
		<category><![CDATA[R&D]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/non-classifiee/dropless-cataract-surgery/</guid>

					<description><![CDATA[<p>Year: 2016, ESCRS Authors:  Giardini P.; Hauranieh N.; Giardini P.; D’Amato Tóthóva J.   Purpose: Standardization of dropless cataract surgery consisting in minimal preoperative preparation and elimination of intraoperative BSS irrigation. Setting: POLIVISUS, via A Moro 34, Brescia, Italy, Private Ophthalmology Clinic. Methods: Sixty cataract patients were enrolled in a prospective study. “Dropless Surgery  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/dropless-cataract-surgery/">Dropless cataract surgery</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-8 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-14 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-9 hover-type-none"><img decoding="async" width="200" height="200" title="ESCRS 200" src="https://alchimiasrl.com/wp-content/uploads/2018/11/escrs-200-2.png" alt class="img-responsive wp-image-12350" srcset="https://alchimiasrl.com/wp-content/uploads/2018/11/escrs-200-2-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/11/escrs-200-2-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/11/escrs-200-2-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/11/escrs-200-2.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-23"><p><strong>Year:</strong> 2016, ESCRS</p>
<p><strong>Authors: </strong> Giardini P.; Hauranieh N.; Giardini P.; D’Amato Tóthóva J.</p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-15 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-24"><p><strong>Purpose</strong>: Standardization of dropless cataract surgery consisting in minimal preoperative preparation and elimination of intraoperative BSS irrigation.</p>
<p><strong>Setting</strong>: POLIVISUS, via A Moro 34, Brescia, Italy, Private Ophthalmology Clinic.</p>
<p><strong>Methods</strong>: Sixty cataract patients were enrolled in a prospective study. “Dropless Surgery group” included forty eyes receiving Mydriasert ophthalmic insert (Laboratories Thea, France) and single application of eyeDRO corneal coating (Alchimia, Italy), before surgery. Control group included 20 eyes receiving topical mydriatics (Visufarma, Italy) preoperatively and irrigation with BSS (Alcon, USA) during surgery. All patients underwent phacoemulsification cataract surgery using Infinity equipment (Alcon, USA). Surgeon scored clarity of operative field and ease of manipulation at different intervals. Eye transparency was examined by slit lamp (Nikon, Japan), and epithelial damage by fluorescein staining, 2 hours postoperatively. All patients filled a self-assessment questionnaire.</p>
<p><strong>Results</strong>: Corneal transparency and operative field clarity were significantly better in “Dropless Surgery group” than in Control group at each time interval. No eyes in “Dropless Surgery group” required further application of eyeDRO during surgery. Six irrigations were required on average in Control group with use of 13,6ml BSS per procedure. Frequency and volume of irrigation were increased in eyes with reduced transparency. Two hours postoperatively, 10% and 57% of patients showed moderate fluorescein staining in Dropless Surgery and Control group, respectively. 20% of patients in “Dropless Surgery group” reported foreign body sensation 24h postop compared to 86% in control group.</p>
<p><strong>Conclusions</strong>: Dropless cataract surgery allowed to increase significantly the clarity of the operative field, facilitated surgical manipulation and improved patient comfort as compared to BSS irrigation procedure. Dropless cataract surgery permitted to minimize the variability related to preoperative preparation and intraoperative irrigation, and then resulted in simplification and standardization of the outcome of the phacoemulsification cataract surgery.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/dropless-cataract-surgery/">Dropless cataract surgery</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Enhanced clarity in cataract patients with poor visibility of the operative field</title>
		<link>https://alchimiasrl.com/enhanced-clarity-in-cataract-patients-with-poor-visibility-of-the-operative-field/</link>
		
		<dc:creator><![CDATA[fabrizio.penso]]></dc:creator>
		<pubDate>Thu, 22 Sep 2016 12:01:44 +0000</pubDate>
				<category><![CDATA[ESCRS]]></category>
		<category><![CDATA[eyeDRO]]></category>
		<category><![CDATA[Meeting presentations]]></category>
		<category><![CDATA[Ophthalmic gels]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Présentations de R&D]]></category>
		<category><![CDATA[R&D]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/non-classifiee/enhanced-clarity-in-cataract-patients-with-poor-visibility-of-the-operative-field/</guid>

					<description><![CDATA[<p>Year: 2016, ESCRS Authors: Giardini P.; Hauranieh N.; Giardini P.; D’Amato Tóthóva J.   Purpose: To report the cases of cataract patients characterized by poor visibility of the operative field which was significantly improved with use of eyeDRO gel. Setting: POLIVISUS, private ophthalmology clinic, via A Moro 34, Brescia, Italy. Methods: Cataract patients with  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/enhanced-clarity-in-cataract-patients-with-poor-visibility-of-the-operative-field/">Enhanced clarity in cataract patients with poor visibility of the operative field</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-9 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-16 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-10 hover-type-none"><img decoding="async" width="200" height="200" title="ESCRS 200" src="https://alchimiasrl.com/wp-content/uploads/2018/11/escrs-200-2.png" alt class="img-responsive wp-image-12350" srcset="https://alchimiasrl.com/wp-content/uploads/2018/11/escrs-200-2-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/11/escrs-200-2-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/11/escrs-200-2-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/11/escrs-200-2.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-25"><p><strong>Year:</strong> 2016, ESCRS</p>
<p><strong>Authors:</strong> Giardini P.; Hauranieh N.; Giardini P.; D’Amato Tóthóva J.</p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-17 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-26"><p><strong>Purpose</strong>: To report the cases of cataract patients characterized by poor visibility of the operative field which was significantly improved with use of eyeDRO gel.</p>
<p><strong>Setting</strong>: POLIVISUS, private ophthalmology clinic, via A Moro 34, Brescia, Italy.</p>
<p><strong>Methods</strong>: Cataract patients with poor visibility of the operative field due to severe dry eye syndrome, corneal epithelium damage, cloudy/opaque cornea, deep set eyes and iatrogenic corneal abrasions are described. All patients received topical anesthetics and Mydriasert ophthalmic insert (Laboratories Thea, France) preoperatively and continuous 2-mm layer of eyeDRO gel (Alchimia, Italy) as corneal surface coating before surgery. All patients underwent phacoemulsification cataract surgery using Infinity equipment (Alcon, USA). Surgeon scored intraoperative clarity of operative field at different intervals and all the surgeries were filmed.</p>
<p><strong>Results</strong>: In patients with severe dry eye, corneal epithelium damage, iatrogenic corneal abrasions, the application of the eyeDRo coating completely reestablished the transparency and visibility of the operative field. In deep set eyes the single application of the gel protected the corneal surface during all the surgery and facilitated the manipulation. Pseudoexfoliation syndrome was clearly detected in eyeDRO treated eye thank to the excellent intraocular visibility.</p>
<p><strong>Conclusions</strong>: In patients characterized by poor visibility of the operative field during phacoemulsification cataract surgery, the single eyeDRO gel application restored visibility and protection of corneal surface significantly better than BSS irrigation.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/enhanced-clarity-in-cataract-patients-with-poor-visibility-of-the-operative-field/">Enhanced clarity in cataract patients with poor visibility of the operative field</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Pars Plana Vitrectomy Alone for the Management of Pseudophakic Rhegmatogenous Retinal Detachment with Only Inferior Breaks</title>
		<link>https://alchimiasrl.com/pars-plana-vitrectomy-alone-for-the-management-of-pseudophakic-rhegmatogenous-retinal-detachment-with-only-inferior-breaks/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Thu, 28 Jul 2016 15:29:41 +0000</pubDate>
				<category><![CDATA[HPF]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Perfluorocarbons]]></category>
		<category><![CDATA[Publications]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/non-classifiee/pars-plana-vitrectomy-alone-for-the-management-of-pseudophakic-rhegmatogenous-retinal-detachment-with-only-inferior-breaks/</guid>

					<description><![CDATA[<p>Year: 2016 Authors: Martínez-Castillo V. J.; García-Arumí J.; Boixadera A.     Ophthalmology 123(7): 1563-9, 2016 Online version  This is a: Publication   Purpose: To report the surgical results of primary pseudophakic  rhegmatogenous retinal detachment (RRD) with only inferior retinal breaks (IRBs) repaired by pars plana vitrectomy (PPV) alone and complete drainage  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/pars-plana-vitrectomy-alone-for-the-management-of-pseudophakic-rhegmatogenous-retinal-detachment-with-only-inferior-breaks/">Pars Plana Vitrectomy Alone for the Management of Pseudophakic Rhegmatogenous Retinal Detachment with Only Inferior Breaks</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-10 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-18 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-27"><p><strong>Year: </strong>2016</p>
<p><strong>Authors:</strong> Martínez-Castillo V. J.; García-Arumí J.; Boixadera A.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:0px;margin-bottom:0px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-28"><p>Ophthalmology 123(7): 1563-9, 2016<br />
<a href="http://www.ncbi.nlm.nih.gov/pubmed/27126928">Online version</a></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-29"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-19 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-30"><p><strong>Purpose:</strong> To report the surgical results of primary pseudophakic  rhegmatogenous retinal detachment (RRD) with only inferior retinal breaks (IRBs) repaired by pars plana vitrectomy (PPV) alone and complete drainage of subretinal fluid.</p>
<p><strong>Design:</strong> Prospective, interventional cohort study.</p>
<p><strong>Participants:</strong> A total of 147 consecutive pseudophakic eyes of 147 patients with primary RRD with causative inferior breaks.</p>
<p><strong>Methods:</strong> All eyes underwent PPV alone and complete drainage of subretinal fluid, with air, 20% sulfur hexafluoride (SF6), or 12% perfluoropropane (C3F8) as tamponade and with no face-down position in the postoperative period.</p>
<p><strong>Main Outcome Measures:</strong> Postoperative primary and final anatomic outcome, visual acuity, and complications.</p>
<p><strong>Results:</strong> The patient population consisted of 44 women (30%) and 103 men (70%) with a mean age of 60.812.9 years. The mean follow-up period was 24.919.4 months. The mean number of quadrants affected was 2.4 (range, 1e4). A single break was present in 90 cases (61.2%), and 2 to 4 breaks were present in 57 cases (38.8%). The macula was found to be detached in 118 cases (80.3%) and attached in 29 cases (19.7%) intraoperatively.<br />
Of 152 breaks located between 5 and 7 clock-hours, 124 breaks (81.6%) were located outside the limits of the gas bubble on the first or third day postoperatively. Initial reattachment was achieved in 139 cases (94.5%; 95% confidence interval, 89.5e97.6). Final reattachment was achieved in 147 cases (100%). Two cases (1.3%) redetached because of new or missed retinal breaks. Six cases (4.1%) redetached because of incomplete retinal adhesion of the treated break(s). Mean preoperative best-corrected visual acuity (BCVA) was 1.110.59 logarithm of the minimum angle of resolution (logMAR). The mean final postoperative BCVA was 0.420.33 logMAR.</p>
<p><strong>Conclusions:</strong> Pars plana vitrectomy alone with complete drainage of subretinal fluid achieves a high reattachment rate in the management of primary pseudophakic RRD due to IRBs.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/pars-plana-vitrectomy-alone-for-the-management-of-pseudophakic-rhegmatogenous-retinal-detachment-with-only-inferior-breaks/">Pars Plana Vitrectomy Alone for the Management of Pseudophakic Rhegmatogenous Retinal Detachment with Only Inferior Breaks</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
